Flash Finance

Kilitch Drugs (India) LimitedKILITCHCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹230.40
MCap ₹806 Cr · P/E 27.6
Kilitch Drugs (India) Limited — Stock analysis & AI research Kilitch Drugs (India) Limited — Seasonality — best & worst months Kilitch Drugs (India) Limited — Technical setup — score, trend, support & resistance Kilitch Drugs (India) Limited — Live exchange announcements
📋 High Profit Growth Stocks 📈 MACD Bearish Crossover📈 Strong Trend Stocks (ADX > 25)📈 Bullish EMA Alignment📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹45 Cr
Sales · Jun 2026
+4.0% YoY
₹3 Cr
Operating Profit · Jun 2026
-10.1% YoY
6.5%
OPM % · Jun 2026
-14.5% YoY
₹2 Cr
Net Profit · Jun 2026
-13.0% YoY
₹0.83
EPS · Jun 2026
-55.9% YoY

📝 Kilitch Drugs (India) Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Kilitch Drugs (India) Limited reported revenue of ₹45 crore for the quarter ended June 2026 (Q1 FY27), up 4.0% from ₹43 crore in the same quarter last year, and down 49.9% sequentially over the March 2026 quarter.

Net profit fell 13.0% year-on-year to ₹2 crore, from ₹2 crore. Earnings per share (EPS) came in at ₹0.83.

Operating profit stood at ₹3 crore — an operating margin (OPM) of 6.5%, compared with 7.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Kilitch Drugs (India) Limited posted revenue of ₹235 crore, a growth of 18.7% over FY25, with a net profit of ₹29 crore (up 20.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹237 crore with a net profit of ₹29 crore.

Valuation snapshot

At the current price of ₹230.40, KILITCH has a market capitalisation of ₹806 crore and a trailing P/E of about 27.6.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 13th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 63.77%, public shareholders 35.62%, foreign institutional investors (FIIs) 0.11%, domestic institutional investors (DIIs) 0.50% of Kilitch Drugs (India) Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹806 Cr
Current Price ?
₹230.4
P/E ?
27.58above ind
Industry P/E ?
21.30
P/B ?
2.88
P/S ?
3.40
P/FCF ?
-10.60
Enterprise Value ?
₹895 Cr
EV/EBITDA ?
24.66
PEG ?
0.61
Earnings Yield ?
3.6%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹237 Cr
OPM ?
15.3%
Profit after tax (TTM) ?
₹29 Cr
EPS (TTM) ?
₹8.35
ROCE ?
14.0%
ROE ?
10.4%
ROA ?
6.4%
Growth
Sales — latest qtr ?
₹45 Cr
PAT — latest qtr ?
₹2 Cr
YoY qtr sales growth ?
4.0%
YoY qtr profit growth ?
-13.0%
Sales growth (3y) ?
19%
Sales growth (5y) ?
28%
Profit growth (3y) ?
45%
Profit growth (5y) ?
60%
Financial Health
Debt ?
₹89 Cr
Debt to Equity ?
0.32
Interest Coverage ?
5.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
63.77%
Change in promoter holding ?
-5.46%
Pledged percentage ?
N/A
Market
Return 3 months ?
26.5%
Return 6 months ?
70.6%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 4537413245334756614349549045 +4.0% -49.9%
Operating Profit 6692726915356223 -10.1% -86.7%
Other Income 11030352237203 +13.3% +491.2%
Interest 11211201221111 -42.7% -39.1%
Depreciation 11121111111111 +29.7% +11.6%
Profit Before Tax 54735210814396204 +12.0% -80.9%
Net Profit 3352409610284152 -13.0% -86.8%
EPS 1.052.152.931.852.240.835.363.716.471.884.972.504.240.83 -55.9% -80.4%
OPM % 13.3% 16.9% 20.9% 7.2% 15.8% 5.0% 12.8% 15.6% 23.8% 7.6% 10.3% 11.4% 24.7% 6.5% -14.5% -73.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹198 Cr ₹235 Cr ₹237 Cr +18.7%
Operating Profit ₹31 Cr ₹37 Cr ₹36 Cr +17.7%
OPM % 15.67% 15.54% 15.29% -0.8%
NPM % 12.38% 12.53% 12.31% +1.2%
Other Income ₹11 Cr ₹11 Cr ₹12 Cr +0.7%
Depreciation ₹3 Cr ₹4 Cr ₹4 Cr +16.5%
Interest ₹5 Cr ₹6 Cr ₹5 Cr +10.2%
EBIT ₹28 Cr ₹33 Cr ₹32 Cr +17.9%
PBT ₹34 Cr ₹39 Cr ₹39 Cr +13.4%
Tax ₹10 Cr ₹9 Cr ₹10 Cr -4.0%
Net Profit ₹25 Cr ₹29 Cr ₹29 Cr +20.1%
EPS ₹16.37 ₹13.59 ₹12.54 -17.0%
Material Cost ₹106 Cr ₹126 Cr ₹123 Cr +19.0%
Employee Cost ₹11 Cr ₹14 Cr ₹16 Cr +26.4%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 16161635 +118.8%
Reserves 136160186245 +31.7%
Borrowings 22324989 +81.6%
Other Liabilities 46326189 +45.9%
Total Liabilities 220240313458 +46.3%
Fixed Assets 64626467 +4.7%
CWIP 4647140 +197.9%
Investments 62727275 +4.2%
Other Assets 90100129176 +36.4%
Total Assets 220240313458 +46.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 3-21824 +33.3%
Cash from Investing Activity 8-8-40-100 -150.0%
Cash from Financing Activity -191382 +530.8%
Net Cash Flow 10-1-96 +166.7%
Free Cash Flow -1-8-29-76 -162.1%
CFO/OP 39%23%82%94% +14.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 142149156186 +19.2%
Inventory Days 10185333 -37.7%
Days Payable 200118189230 +21.7%
Cash Conversion Cycle -485020-11 -155.0%
Working Capital Days -43056130 +132.1%
ROCE % 10%13%16%14% -12.5%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 69.23%63.77%63.77%63.77%63.77% +0.0%
Public 30.77%36.22%36.23%36.22%35.62% -1.7%
No. of Shareholders 10,37910,92912,04311,78512,319 +4.5%
FIIs ————0.11% —
DIIs ————0.50% —

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Kilitch Drugs (India) Limited's revenue in Q1 FY27?
Kilitch Drugs (India) Limited reported revenue of ₹45 crore for the quarter ended June 2026 (Q1 FY27), up 4.0% from ₹43 crore in the same quarter last year, and down 49.9% sequentially over the March 2026 quarter.
What was Kilitch Drugs (India) Limited's net profit in Q1 FY27?
Net profit fell 13.0% year-on-year to ₹2 crore, from ₹2 crore. Earnings per share (EPS) came in at ₹0.83.
What is KILITCH's market capitalisation and P/E ratio?
At the current price of ₹230.40, KILITCH has a market capitalisation of ₹806 crore and a trailing P/E of about 27.6.
Who owns Kilitch Drugs (India) Limited? (shareholding pattern)
As of Sep 2026, promoters held 63.77%, public shareholders 35.62%, foreign institutional investors (FIIs) 0.11%, domestic institutional investors (DIIs) 0.50% of Kilitch Drugs (India) Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI